Institutions · Entity Annotation Prototype (beta)

3articles mentioning institutions

5institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: cohort A ×

cohort A

This institution is selected. Its supporting articles are shown below.

Cohort A3

Articles mentioning cohort A

3 articles · page 1 of 1

4CPS-209 Retrospective monocentric study evaluating the proper use and effectiveness of TYRX absorbable antibacterial envelope in a rhythmology department

ejhpharm · abstract · 2026-03-18 · 2 matching annotations

90.6%

Cohort A cohort B rhythmology department HAS C. albicans E. dermatitidis TYRX HAS

…comparing data from two cohorts: those not implanted with TYRX (Cohort A) and those implanted with TYRX (Cohort B).Results A total of 58…

534 A Phase 1 dose-escalation and expansion study evaluating the safety, efficacy, and pharmacokinetics of EVOLVE104 in subjects with advanced urothelial and squamous cell carcinomas

jitc · abstract · 2025-11-04 · 2 matching annotations

84.5%

Cohort B Cohort A EVOLVE104 EIU-104101 urothelial carcinoma squamous cell carcinomas FDA EVOLVE TCEs transitional cell carcinomas of the urinary tract locally advanced or metastatic solid tumors

…1:1 to two doses to determine the recommended phase 2 dose; and Cohort B, which will enroll up to 40 subjects in relevant indications ot…

Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial

bmjopen · abstract · 2026-03-23 · 1 matching annotations

84.8%

Shanghai Chest Hospital Cohort A lung cancer bevacizumab NSCLC intrathecal pemetrexed chemotherapy

…ve, investigator-initiated phase Ia clinical trial sponsored by Shanghai Chest Hospital, involving patients with advanced NSCLC and LM. Participants wi…